Opioid Settlement Money to Fund Addiction Research Center

Oklahoma dropped its lawsuit against OxyContin-maker Purdue Pharma in exchange for a National Center for Addiction Studies and Treatment in Tulsa.

Written byAshley Yeager
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

ABOVE: OSU medical center
WIKIMEDIA, RYTYHO, USA

Oklahoma State University plans to launch a National Center for Addiction Studies and Treatment using funds from a lawsuit settlement with OxyContin-maker Purdue Pharma, Science reported yesterday (April 2).

According to the settlement, Purdue Pharma and the family that owns the company is slated to provide a $177 million endowment for the national center and $20 million over five years for anti–opioid-addiction drugs such as naloxone. The money will build out the university’s Center for Wellness and Recovery, which opened in 2017 and was designed to train doctors on treating addiction, study its causes, help those suffering from opioid use disorder, and educate the public about the opioid epidemic.

“Our mission is to train primary care physicians to work in rural and underserved areas,” Kayse Shrum, OSU medical school president, tells Science. “And that’s where the [addiction] crisis is most acute. So we began ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Ashley started at The Scientist in 2018. Before joining the staff, she worked as a freelance editor and writer, a writer at the Simons Foundation, and a web producer at Science News, among other positions. She holds a bachelor’s degree in journalism from the University of Tennessee, Knoxville, and a master’s degree in science writing from MIT. Ashley edits the Scientist to Watch and Profile sections of the magazine and writes news, features, and other stories for both online and print.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies